Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression
Open Access
- 28 January 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 604-607
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaJournal of Clinical Oncology, 2025
- Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoireNature Communications, 2025
- MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2023
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpJournal of Clinical Oncology, 2023
- Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)Journal of Hematology & Oncology, 2022
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2021